A MODEL FOR PHARMACOKINETICS AND PHYSIOLOGICAL FEEDBACK AMONG HORMONES OF THE TESTICULAR-PITUITARY AXIS IN ADULT MALE RATS - A FRAMEWORK FOR EVALUATING EFFECTS OF ENDOCRINE ACTIVE COMPOUNDS
Ha. Barton et Me. Andersen, A MODEL FOR PHARMACOKINETICS AND PHYSIOLOGICAL FEEDBACK AMONG HORMONES OF THE TESTICULAR-PITUITARY AXIS IN ADULT MALE RATS - A FRAMEWORK FOR EVALUATING EFFECTS OF ENDOCRINE ACTIVE COMPOUNDS, TOXICOLOGICAL SCIENCES, 45(2), 1998, pp. 174-187
The testicular-hypothalamic-pituitary axis controls reproductive funct
ions in males. A description of the basic physiological interactions i
n adult rats among testosterone, luteinizing hormone (LH), and follicl
e stimulating hormone (FSH) was developed, permitting simulation of ho
rmone levels in testes and blood. This model was used to simulate horm
one levels in intact, castrate, ethane dimethanesulfonate-treated, and
antiandrogen-treated rats. A large gradient of testosterone concentra
tions from testicular interstitial fluid to low levels in peripheral b
lood is created by the testicular blood flow. The dominant feedback lo
op is positive regulation of testosterone synthesis by LH and negative
feedback of testosterone on LH and FSH, The utility of the model for
placing in vitro data in the context of in vivo physiology was illustr
ated for the case of continued synthesis of testosterone by the isolat
ed testes. In the absence of blood flow, very low residual testosteron
e synthesis can substantially increase testosterone concentration in i
solated testes. Effects of an exogenous endocrine active compound were
illustrated by modeling altered LH and FSH regulation by testosterone
in the presence of an antiandrogen acting as a competitive ligand for
the androgen receptor. Increasing concentrations have no effect on st
eady-state hormone levels until sufficient levels of antiandrogen are
achieved to reduce negative feedback of testosterone on LH and FSH. In
summary, a model has been developed that provides a basis for initiat
ing evaluations of key issues of concern for the risk assessment of en
docrine active compounds including in vitro to in vivo extrapolation a
nd their dose-response behaviors. (C) 1998 Society of Toxicology.